Metabolism of arachidonic acid by caruncular and allantochorionic tissues in cows with retained fetal membranes (RFM).
The metabolism of arachidonic acid (AA) by caruncular and allantochorionic tissues and its regulation was studied in normal cows (n = 13) and those with retained fetal membranes (RFM; n = 9). Tissues were taken via the vagina about 6 hours postpartum and incubated for 6 hours in minimum essential medium containing tritiated AA alone or in the presence of oxytocin, platelet activating factor (PAF), epidermal growth factor (EGF) or ionophore calcium (A23187). The metabolites of AA were separated by reverse phase-high pressure-liquid chromatography. Tissue concentrations of prostaglandin F2 alpha (PGF2 alpha) and prostaglandin E2 (PGE2) and plasma 13,14-dihydro-15-keto-PGF2 alpha (PGFM) concentration were also measured by radioimmunoassay. For caruncular tissue, less thromboxane B2 (TXB2) and more 6-keto prostaglandin F1 alpha (PGIM) was synthesized in tissue from the animals with RFM than in the controls. Oxytocin, PAF, EGF and A23187 increased only PGIM production in the control animals; A23187 also decreased TBX2 synthesis. For the allantochorion, more PGE2, leukotriene B4 (LTB4) and PGIM and less TXB2, PGF2 alpha and hydroxyecosatetranoic acids (HETE) was synthesized in tissue from cows with RFM than from animals that delivered normally. All of the substances used in this study increased PGIM, PGF2 alpha and LTB4 and decreased TXB2 production by the allantochorionic tissue in control animals. The metabolism of AA by the allantochorionic tissue seems quantitatively under hormonal control. The metabolism of AA at the level of both maternal and fetal components of the placenta in cows with RFM differed from that seen in animals that expelled the membranes normally.
Centre de Recherche en Reproduction Animale, Universite de Montreal, Faculte de Medecine Veterinaire St-Hyacinthe, Quebec.
H
H
Slama
D
D
Vaillancourt
A K
AK
Goff
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000482:Allantois / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism*; D002118:Calcium / Q000494:pharmacology; D002417:Cattle; D002823:Chorion / Q000187:drug effects / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005260:Female; D006893:Hydroxyeicosatetraenoic Acids / Q000378:metabolism; D007975:Leukotriene B4 / Q000378:metabolism; D010121:Oxytocin / Q000494:pharmacology; D010920:Placenta / Q000187:drug effects / Q000378:metabolism*; D010922:Placenta Diseases / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000494:pharmacology; D011247:Pregnancy; D013929:Thromboxane B2 / Q000378:metabolism
D006893:Hydroxyeicosatetraenoic Acids; D010972:Platelet Activating Factor; D007975:Leukotriene B4; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D016718:Arachidonic Acid; D010121:Oxytocin; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D004815:Epidermal Growth Factor; D015237:Dinoprost; D015232:Dinoprostone; D002118:Calcium